Pharmaceutical composition for preventing and treating chronic obstructive pulmonary disease, comprising Magnolia floss extract, fraction or active fraction thereof as an active ingredient
The present invention relates to a pharmaceutical composition comprising any of an extract of Magnoliae flos , a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient for preventing and treating chronic obstructive pulmonary disease. It was confirmed that the extract of Magnoliae flos , the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-± and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines. Therefore, the extract of Magnoliae flos , the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom can be advantageously used as a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease.
